Perioperative PD-1 antibody tislelizumab plus chemotherapy for locally advanced gastro-oesophageal junction cancer: A prospective, nonrandomized, open-label, phase II trial

被引：0
|
作者：
Nie, Run-Cong
Ding, Ya
Yuan, Shu-Qiang
Li, Yuan-fang
Wang, Wei
Chen, Yongming
Cai, Muyan
Sun, Xiao-wei
Weng, Desheng
Li, Dandan
Zhao, Jingjing
Chen, Xiaojiang
Guan, Yuanxiang
Ma, Luo
Qiu, Haibo
Zhou, Zhi-wei
Zhang, Xiao-Shi
Chen, Ying-bo
机构：
[1] Sun Yat Sen Univ, Sun Yat sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Ctr Canc, Biotherapy Ctr, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China
[4] Sun Yat Sen Univ, Ctr Canc, Melanoma & Sarcoma Med Oncol Unit, Guangzhou, Peoples R China
[5] Sun Yat Sen Univ, Sun Ya Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, Ctr Canc, Guangzhou, Peoples R China
[6] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Ctr Canc, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4083
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial
    Yuan, Shuqiang
    Nie, Run-Cong
    Jin, Ying
    Liang, Cheng-Cai
    Jian, Rui
    Li, Yuan-Fang
    Qiu, Haibo
    Wang, Wei
    Chen, Shi
    Zhang, Dong-Sheng
    Huang, Chun-Yu
    Ling, Yi-Hong
    Yang, Qiu-Xia
    Wang, Zi-Xian
    Guan, Wen-Long
    Chen, Ying-Bo
    Sun, Xiao-Wei
    Zhou, Zhi-Wei
    Wang, Feng
    Xu, Rui-Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Perioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): a prospective, nonrandomized, open-label, phase 2 trial
    Nie, Run-Cong
    Yuan, Shu-Qiang
    Ding, Ya
    Chen, Yong-Ming
    Li, Yuan-Fang
    Liang, Cheng-Cai
    Cai, Mu-Yan
    Chen, Guo-Ming
    Wang, Wei
    Sun, Xiao-Wei
    Weng, De-Sheng
    Li, Dan-Dan
    Zhao, Jing-Jing
    Chen, Xiao-Jiang
    Guan, Yuan-Xiang
    Liu, Zhi-Min
    Liang, Yao
    Luo, Ma
    Chi, Jun
    Qiu, Hai-Bo
    Zhou, Zhi-Wei
    Zhang, Xiao-Shi
    Chen, Ying-Bo
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2025, 10 (01)
  • [3] First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
    Janjigian, Yelena Y.
    Shitara, Kohei
    Moehler, Markus
    Garrido, Marcelo
    Salman, Pamela
    Shen, Lin
    Wyrwicz, Lucjan
    Yamaguchi, Kensei
    Skoczylas, Tomasz
    Bragagnoli, Arinilda Campos
    Liu, Tianshu
    Schenker, Michael
    Yanez, Patricio
    Tehfe, Mustapha
    Kowalyszyn, Ruben
    Karamouzis, Michalis V.
    Bruges, Ricardo
    Zander, Thomas
    Pazo-Cid, Roberto
    Hitre, Erika
    Feeney, Kynan
    Cleary, James M.
    Poulart, Valerie
    Cullen, Dana
    Lei, Ming
    Xiao, Hong
    Kondo, Kaoru
    Li, Mingshun
    Ajani, Jaffer A.
    LANCET, 2021, 398 (10294): : 27 - 40
  • [4] Updated results of perioperative PD-1 antibody toripalimab plus FLOT chemotherapy for locally advanced resectable gastric or gastro-esophageal junction adenocarcinoma: A one-arm open-table phase II trial
    Li, Hongli
    Ge, Shaohua
    Zang, Fenglin
    Ren, Peng
    Cao, Fuliang
    Liu, Rui
    Yang, Yuchong
    Ning, Tao
    Bai, Ming
    Wang, Xia
    Ji, Zhi
    Duan, Jingjing
    Liang, Han
    Ba, Yi
    Deng, Ting
    Deng, Jingyu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
    Bang, Yung-Jue
    Van Cutsem, Eric
    Feyereislova, Andrea
    Chung, Hyun C.
    Shen, Lin
    Sawaki, Akira
    Lordick, Florian
    Ohtsu, Atsushi
    Omuro, Yasushi
    Satoh, Taroh
    Aprile, Giuseppe
    Kulikov, Evgeny
    Hill, Julie
    Lehle, Michaela
    Ruschoff, Josef
    Kang, Yoon-Koo
    LANCET, 2010, 376 (9742): : 687 - 697
  • [6] Fruquintinib plus oxaliplatin combined with S-1 (SOX) as neoadjuvant therapy for locally advanced gastric cancer (GC) or gastro-oesophageal junction adenocarcinoma (GEJ): a multicentre, phase II, single-arm, open-label clinical trial (FRUTINEOGA) protocol
    Wu, Liucheng
    Yan, Haiqing
    Qin, Yuzhou
    Huang, Mingwei
    Wang, Tingan
    Jin, Qinwen
    Wei, Weiyuan
    BMJ OPEN, 2024, 14 (02):
  • [7] Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
    Shitara, Kohei
    Ozguroglu, Mustafa
    Bang, Yung-Jue
    Di Bartolomeo, Maria
    Mandala, Mario
    Ryu, Min-Hee
    Fornaro, Lorenzo
    Olesinski, Tomasz
    Caglevic, Christian
    Chung, Hyun C.
    Muro, Kei
    Goekkurt, Eray
    Mansoor, Wasat
    McDermott, Raymond S.
    Shacham-Shmueli, Einat
    Chen, Xinqun
    Mayo, Carlos
    Kang, S. Peter
    Ohtsu, Atsushi
    Fuchs, Charles S.
    LANCET, 2018, 392 (10142): : 123 - 133
  • [8] Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
    Qiu, Miao-Zhen
    Oh, Do-Youn
    Kato, Ken
    Arkenau, Tobias
    Tabernero, Josep
    Correa, Marcia Cruz
    Zimina, Anastasia, V
    Bai, Yuxian
    Shi, Jianhua
    Lee, Keun-Wook
    Wang, Jufeng
    Poddubskaya, Elena
    Pan, Hongming
    Rha, Sun Young
    Zhang, Ruixing
    Hirano, Hidekazu
    Spigel, David
    Yamaguchi, Kensei
    Chao, Yee
    Wyrwicz, Lucjan
    Disel, Umut
    Cid, Roberto Pazo
    Fornaro, Lorenzo
    Evesque, Ludovic
    Wang, Hongwei
    Xu, Yaling
    Li, Jiang
    Sheng, Tao
    Yang, Silu
    Li, Liyun
    Moehler, Markus
    Xu, Rui-Hua
    BMJ-BRITISH MEDICAL JOURNAL, 2024, 385
  • [9] Perioperative chemotherapy with LP002, an anti-PD-L1 antibody, in patients with resectable gastric and gastroesophageal junction cancer: A prospective, open-label, phase Ib trial.
    Tang, Jialin
    Huang, Jing
    Zhang, Bo
    Qi, Ling
    Dao, Xin
    Wang, Lin
    Li, Yong
    Tian, Yantao
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] Neoadjuvant tislelizumab plus chemotherapy among patients with locally advanced cervical cancer: A prospective, single-arm, phase II trial
    Sheng, Jindong
    Liu, Wenxin
    Liu, Ruoyan
    Liu, Chunyan
    Wang, Bochang
    Liu, Xiangyu
    Xu, Changxiao
    Fu, Xin
    Wang, Ke
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S14 - S14
12345